Replies to post #246056 on Biotech Values

[DewDiligence]

MRK acquires CDTX for $221.50/sh cash—a 109% premium to yesterday’s close:

https://www.businesswire.com/news/home/20251114185276/en/Merck-to-Acquire-Cidara-Therapeutics-Inc.-Diversifying-Its-Portfolio-to-Include-Late-Phase-Antiviral-Agent

The nominal deal value is $9.2B.